New York City interim police commissioner says federal authorities searched his homes
Marxist Dissanayake leads early vote count in Sri Lanka's presidential election
Trial in daytime ambush of rapper Young Dolph 3 years ago to begin in Memphis
Hezbollah, Israel exchange heavy fire after deadly Israeli strike
Over 100 rockets fired from Lebanon into Israel, with some hitting near northern city of Haifa
At least 19 killed as methane leak causes explosion at eastern Iran coal mine, state TV reports
Japan PM hopeful Ishiba sees 'room' for corporate tax hike, Kyodo reports
Southwest Airlines warns staff of 'tough decisions' ahead, Bloomberg reports
GM to lay off about 1,700 workers at Kansas plant
White Sox lose 119th game to tie the AL record as the Padres win 6-2 behind 3 home runs
No. 1 Texas keeps rolling behind Manning and Blue and routs ULM 51-3 in last game before SEC play
NEW YORK (Reuters) - Moderna Inc respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.
In their clinical trials, GSK's RSV vaccine Arexvy was 78% effective in preventing severe RSV over a second year and Pfizer's was 78% effective through a second RSV season.
Moderna presented the data at a meeting of the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. The drugmaker has previously cautioned against comparing its vaccine to rivals, noting that the trials were not head-to-head and used different case definitions for RSV disease.
(This story has been corrected to eliminate the word 'midway', to reflect that Pfizer's data was from the end of the season, in paragraph 2)
(Reporting by Michael Erman)
